Freshpet announced it will report third quarter 2026 financial results on November 4, 2026, before market open, followed by a conference call with executive management at 8:00 a.m. ET. The call will be available via phone and live internet broadcast.

Freshpet (FRPT) closed at $61.33, up 1.78% but down 14.21% over the past month. The company is expected to report earnings of $0.4 per share (down 13.04% YoY) with revenue projected at $308.51 million (up 6.81% YoY). For the full year, analysts expect earnings to decline 51.89% while revenue grows 10.73%. The stock carries a Zacks Rank of #3 (Hold) with a Forward P/E of 47.64, significantly above its industry average of 13.62.

Freshpet (FRPT) declined 2.02% to $60.13 in the latest session, falling 19.83% over the past month. The company is projected to report a 17.39% year-over-year earnings decline for the upcoming quarter, though quarterly revenue is expected to grow 6.81%. With a Zacks Rank of #4 (Sell) and a Forward P/E of 35.58 significantly above the industry average of 14, the stock faces headwinds despite modest revenue growth expectations.

Freshpet stock declined 1.71% to $62.68, underperforming the S&P 500. The stock has fallen 12.22% over the past month, significantly lagging its sector. Analysts expect earnings to decline 17.39% year-over-year, though revenue is projected to grow 6.81%. The company carries a Zacks Rank #4 (Sell) rating and trades at a premium valuation with a Forward P/E of 36.97 versus its industry average of 13.84.

Freshpet stock declined 4.21% to $67.28, underperforming the broader market. The company faces headwinds with expected EPS down 17.39% year-over-year for the upcoming quarter, though revenue is projected to grow 6.81%. Annual earnings are anticipated to decline 34.47% while revenue grows 10.73%. The stock carries a Zacks Rank of #4 (Sell) and trades at a Forward P/E of 40.72, significantly above its industry average of 14.33.

Freshpet CEO William Cyr sold 87,905 shares for $6.6 million on August 21-24, 2026, as part of a pre-arranged trading plan following the exercise of ~168,000 options. Despite the sale, his total equity holdings increased to ~567,000 shares. The transaction appears to be routine executive compensation rather than a bearish signal on the stock. Freshpet trades at 39x 2027 estimated earnings with 15% recent sales growth, though the valuation is considered premium for a non-high-growth company.

The global pet treats market is projected to grow at a CAGR of 8.9% from USD 38.40 billion in 2026 to USD 58.71 billion by 2031, driven by increasing pet ownership, pet humanization, and rising demand for premium, functional treats with natural ingredients. Jerky and meat-based treats dominate the market, while freeze-dried products and e-commerce channels show the fastest growth. Asia Pacific is expected to be the fastest-growing region.

Freshpet's Board of Directors authorized a $150 million share repurchase program, reflecting the company's strong financial position and balance sheet. The company plans to fund repurchases through existing cash, operational cash flow, and future borrowings while maintaining its primary focus on investing in business growth in the fresh pet food market.

Lowey Dannenberg P.C. is investigating Freshpet Inc. (NASDAQ: FRPT) for potential federal securities law violations following the BBB National Programs' recommendation that the company discontinue claims that its dog food is 'human grade.' The investigation concerns whether the company and its executives provided investors with accurate and complete information.

The National Advertising Division found that Freshpet's dog food advertisements were misleading, specifically claims that their product is made 'the same way you make healthy food for people,' implying human-grade quality. Following this ruling on March 17, 2026, Freshpet's stock declined nearly 11%, dropping $7.95 per share from $75.37 to $67.42. A securities litigation law firm is now investigating potential federal securities law violations on behalf of affected investors.

Pomerantz LLP is investigating potential securities fraud claims against Freshpet, Inc. following a BBB National Programs ruling that found certain dog food claims unsupported, particularly regarding 'human grade' labeling. The company agreed to comply with the recommendation, but the announcement triggered a 10.55% stock price decline on March 17, 2026.

The BBB National Programs' National Advertising Division found that Freshpet's dog food advertisements were misleading, specifically claims that their product is made 'the same way you make healthy food for people,' implying human-grade quality. Following this ruling on March 17, 2026, Freshpet's stock declined nearly 11% from $75.37 to $67.42 per share. A securities litigation law firm is investigating potential federal securities law violations on behalf of affected investors.